tiprankstipranks
Trending News
More News >

Senzime’s Licensee Secures US and UK Approvals for HN-100 Module

Story Highlights
  • Senzime’s licensee, Fukuda Denshi, received approvals to launch the HN-100 module in the US and UK.
  • This expansion enhances Senzime’s market presence and revenue potential through its collaboration with Fukuda.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Senzime’s Licensee Secures US and UK Approvals for HN-100 Module

Don’t Miss TipRanks’ Half-Year Sale

Senzime AB ( (SE:SEZI) ) has shared an announcement.

Senzime AB announced that its licensee, Fukuda Denshi, has obtained FDA and UKCA approvals to introduce the HN-100 neuromuscular transmission module in the US and UK. This development is significant for Senzime as it expands Fukuda’s market reach, leveraging Senzime’s TetraGraph® technology, and potentially increasing revenue through manufacturing and royalty agreements.

More about Senzime AB

Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.

Average Trading Volume: 320,909

Current Market Cap: SEK843.6M

For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1